Relationship of HHV-6B Virus to Seizures and Brain Injury

This study has been terminated.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00597285
First received: January 8, 2008
Last updated: November 5, 2013
Last verified: November 2013
  Purpose

This study will look for evidence that a virus called HHV-6B may be related to seizures and to a form of brain injury called mesial temporal sclerosis that is associated with seizures. The study will use new, more sensitive brain scans to try to detect brain regions that might be affected by the virus and will examine cerebrospinal fluid (CSF, the fluid that bathes the brain and spinal cord) for evidence of the virus as well.

Healthy volunteers and people with seizures uncontrolled by anti-epileptic drugs who are between 18 and 45 years of age may be eligible for this study. Candidates are screened with a physical examination and laboratory tests.

Participants undergo the following procedures:

  • PET scan. This test uses a radioactive chemical called 18FDG, which is detected by the PET scanner to obtain images of the brain. The subject lies on a table with his or her head positioned in the scanner. A swimming cap with a small light reflector is placed on the head to monitor the position of the head during the scan. A catheter (plastic tube) is inserted into an artery at the wrist or elbow crease of the arm for obtaining blood samples during the scan, and a second catheter is placed in a vein in the other arm for injecting the 18FDG. The scan takes up to 2 hours. A second scan may be done over an additional 15 minutes.
  • MRI. This test uses a strong magnetic field and radio waves to obtain images of the brain. The subject lies on a table that can slide in and out of a metal cylinder surrounded by a magnetic field. Most scans last between 45 and 90 minutes.
  • Lumbar puncture. The subject sits upright or lies on a table with the knees curled to the chest for this procedure. A local anesthetic is injected to numb the skin and a needle is inserted in the space between the bones in the lower back where the CSF circulates below the spinal cord. A small amount of fluid is collected through the needle.
  • Blood tests. About 4 tablespoons of blood are drawn for viral tests.

Condition
Epilepsy
HHV6B Infection

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: HHV6B in Epilepsy Imaging and CSF Studies

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Detection of evidence for HHV6 infection in CSF

Secondary Outcome Measures:
  • Detection of lesions on 7T compared to 3T MRI

Enrollment: 33
Study Start Date: January 2008
Estimated Study Completion Date: November 2013
Detailed Description:

Objectives: 1) to attempt to detect specific patterns of hippocampal injury in patients with temporal lobe epilepsy that may be associated with HHV-6B infection; 2) To attempt to detect evidence for persistent HHV6 infection in CSF in patients with refractory temporal lobe epilepsy. 3) to obtain preliminary pilot data on the ability of high resolution structural to detect abnormalities in epilepsy patients not seen with standard scanners.

Study Population: 45 patients with localization-related epilepsy; 45 healthy volunteers

Design: 1) imaging with a 7T MRI magnetic resonance scanner; 2) Lumbar puncture. 3) blood sampling

Main outcome measure: 1) Detection of evidence for HHV6 infection in CSF

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Patients will be avaluated for participation under screening protocol 01-N-0139.

Patients

Male and female subjects age 18 to 55

Subjects with seizures uncontrolled by antiepileptic drugs

Subjects with no other illnesses, or taking other substances or medicines that could interfere with the study

Healthy Controls

Male and female subjects age 18 to 55.

EXCLUSION CRITERIA:

Patient

Subjects who are pregnant or breast feeding.

Subjects with any medical condition that could interfere with the study.

Subjects who are taking drugs that significantly reduce blood clotting such as Coumadin or Warfarin.

Healthy Volunteers

Subjects who are pregnant or breast feeding

Subjects who have any medical condition or be taking any substance or medication that could interfere with the study

Subjects who are taking drugs that significantly reduce blood cloting such as Coumadin or Warfarin

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00597285

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Principal Investigator: William H Theodore, M.D. National Institute of Neurological Disorders and Stroke (NINDS)
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00597285     History of Changes
Other Study ID Numbers: 080027, 08-N-0027
Study First Received: January 8, 2008
Last Updated: November 5, 2013
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
18-F-Fluoro-2-Deoxy-D-Glucose (FDG)
Magnetic Resonance
Epilepsy
HHV-6B
Healthy Volunteer
HV

Additional relevant MeSH terms:
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on August 21, 2014